Considering ALKBH5 as an “eraser” in the demethylation process, combining with the results of our study, we attempted to explore the dysregulation of ALKBH5 in the pathogenesis of patients with PAAD. This evidence concerns the gene ALKBH5 and pancreatic adenocarcinoma.